DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rdmjs8/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023" report to their offering.
The total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%)
The publisher expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic.
Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
France represents one of the smallest in terms of overall ACS drug sales. Next to the US market, Germany commands the largest global market share for the sale of ACS drugs. Italy's contribution to global sales in both 2013 and 2023 falls in the middle of the sales distribution for the 7MM covered in this forecast. Of the 7MMs that were forecast in this report, Spain's share of global sales is the smallest for both the 2013 base year and the final forecast year of 2023. Of the markets forecast here, the UK commands the third largest market share in both the 2013 base year and in 2023.
- Fibrinolytic (Thrombolytic) Drugs - Tissue Plasminogen Activator (tPA)
- Brilinta (ticagrelor)
- Effient (prasugrel)
- Integrilin (eptifibatide)
- Angiomax (bivalirudin)
- Arixtra (fondaparinux) and the Heparins
- Statins - HMG-CoA Reductase Inhibitors
- Beta-Adrenergic Receptor Antagonists (Beta Blockers)
- Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors
Unmet Need and Opportunity
- Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
- Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
- LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
- Antidotes for New Oral Anticoagulants (NOACs)
- Blood-Thinning Agents with Significantly Reduced Bleeding Risks
Promising Drugs in Clinical Development
- Xarelto (rivaroxaban)
- Zontivity (vorapaxar)
- Alirocumab (RGN727)
- Evolocumab (AMG 145)
- Bococizumab (PF-04950615)
For more information visit http://www.researchandmarkets.com/research/rdmjs8/pharmapoint